Fuda Cancer Hospital
| Chine | Turquie | Espagne | |
| Élimination du cancer du foie | de $21,500 | de $10,800 | de $35,000 |
| Élimination du cancer du côlon | de $17,500 | de $14,400 | de $18,000 |
| Une greffe de moelle osseuse | de $55,000 | de $36,000 | de $71,782 |
| Thérapie par faisceau de protons | de $36,500 | de $70,000 | de $25,138 |
| Système robotique Da Vinci | de $24,500 | de $9,500 | de $17,000 |
Bookimed ne rajoute pas de frais pour les traitements de Oncologie. Les tarifs proviennent des listes de prix officielles des cliniques. Vous payez directement à la clinique pour votre traitement à votre arrivée dans le pays.
Bookimed s'engage pour votre sécurité. Nous ne travaillons qu'avec des établissements médicaux qui respectent des normes internationales élevées dans le traitement de Oncologie et qui possèdent les licences nécessaires pour accueillir des patients internationaux dans le monde entier.
Bookimed offre une assistance experte gratuite. Un coordinateur médical personnel vous accompagne avant, pendant et après votre traitement, en résolvant tous les problèmes. Vous n'êtes jamais seul dans votre parcours de traitement de Oncologie.
Zhang Yanjun, MD, is a Chief Physician and Master’s Supervisor with 30 years of experience in tumor imaging and radiation oncology. He treats both pediatric and adult patients. His focus includes primary and secondary tumors, neuro-oncology, and stereotactic radiotherapy.
He is proficient in radiotherapy for cancers of the lung, liver, nasopharynx, head and neck, esophagus, breast, rectum, cervix, and prostate, as well as lymphoma and central nervous system tumors.
He is a member of the Central Nervous System Tumor Radiotherapy Group of the Second Committee of the Radiation Oncology Physicians Branch of the Chinese Medical Doctor Association. He serves on the Executive Committee of the First Chinese Oncology Radiation Therapy Cooperation Group of the World Association of Chinese Oncology Physicians. He is also a member of the National Digestive Oncology Expert Committee of the Radiation Oncology Professional Committee of the Wu Jieping Medical Foundation. He was a visiting scholar twice at leading U.S. cancer radiotherapy centers. He has published 46 papers in core journals and international conferences.
Près de 10 000 cryochirurgies pratiquées – Le professeur Niu Lizhi dirige le programme d'oncologie mini-invasive de l'hôpital de cancérologie Fuda.
Dr. Liuying leads the Oncology Ward at Jinshazhou Hospital, Guangzhou University of Chinese Medicine. Clinical focus includes hepatocellular carcinoma, cholangiocarcinoma, and lung and colorectal cancers. Dr. Liuying has special expertise in melanoma and melanoma liver metastasis. Interventional skills include MWA, RFA, cryoablation, and radioactive seed implantation for non-vascular, minimally invasive tumor ablation.
Research: participated in two Guangdong Provincial science and technology projects. Contributed to the 2014 Expert Consensus for Thermal Ablation of Primary and Metastatic Lung Tumors. Published in the Chinese Journal of Lung Cancer. Compiled Selected Cases of Microwave Ablation for Lung Tumors and Selected Cases of Microwave Ablation for Liver Tumors.
Appointments: Standing Committee Member, Youth Committee of Intra-Tumor Brachytherapy Medicine, China Medical Education Association. Standing Committee Member, Minimally Invasive Interventional Medicine Professional Committee, Guangdong Primary Medical Association.
Dr. LV Xiao Jun is the Executive Director of the Department of Medical Oncology. He is a national expert in psycho-oncology and has 30 years of clinical experience. He previously served at the First Affiliated Hospital of Xiamen University. He is a recognized expert in cancer treatment and lung cancer care in Fujian Province.
Clinical focus: comprehensive care for solid tumors, including lung, breast, and gastrointestinal cancers; palliative care in oncology; and screening and treatment for psychological distress.
Appointments: Standing Committee Member (third term), Psycho-Oncology Committee, Chinese Anti-Cancer Association; Standing Committee Member (third term), Lung Cancer Committee, Fujian Anti-Cancer Association.
International patients in China access oncology treatments like Chimeric Antigen Receptor T-cell (CAR-T) therapy, NanoKnife, and cryosurgery. JCI-accredited facilities in Guangzhou and Beijing provide precision radiotherapy and immunotherapy. These centres specialise in organ-preserving techniques for solid tumours and blood cancers.
Bookimed Expert Insight: China's oncology landscape is defined by its massive volume. Clinics like Fuda Cancer Hospital have treated over 30,000 international patients. This scale allows surgeons to perform rarer procedures like NanoKnife hundreds of times annually. For Australians, this frequent experience means doctors handle complex cases often seen less at home.
Patient Consensus: Patients note that Chinese clinics focus on organ preservation when other countries suggest removal. They appreciate the five-star room facilities. They also value medical staff who arrange translators to bridge communication gaps.
International oncology patients in China receive support through dedicated international departments. These teams bridge language and logistical gaps. Major centres like Fuda Cancer Hospital provide JCI-accredited care with multilingual services. Hospitals often assist with S2 medical visas and offer on-site interpreters for complex multidisciplinary team reviews.
Bookimed Expert Insight: Language support tiers vary significantly between public and private hospitals in Guangzhou and Beijing. Clinics with 4.5+ ratings, like Yanda International Hospital, typically combine international protocols with traditional Chinese medicine. These JCI-accredited facilities often provide bilingual paperwork. This is essential for patients returning to the Australian healthcare system.
Patient Consensus: Patients in China often note that native-speaking translators help communication during busy consultations. They suggest bringing translated medical records and hiring a local coordinator. This helps manage appointments, transport, and follow-up schedules comfortably.
International patients can access experimental cancer clinical trials in China if the trial design allows foreign enrolment. Many local registration trials restrict participation to Chinese citizens. However, Multi-Regional Clinical Trials (MRCTs) actively include global patients. Eligibility requires matching specific diagnostic protocols and securing an S-class medical visa.
Bookimed Expert Insight: A major advantage in China is the concentration of trial capabilities within high-volume tertiary hospitals. Xiamen Humanity Hospital manages 1,000,000 patients annually and is authorised for all drug trial phases. This volume creates a massive data pool. This often leads to faster trial progression compared to smaller Western centres.
Patient Consensus: Patients note that Chinese hospitals often offer hope when domestic treatments fail. They particularly highlight the modern equipment and five-star room facilities. Patients find that native-speaking translators help bridge the language gap. This helps doctors explain complex diagnoses in detail.
Australians seeking oncology care in China should focus on JCI-accredited facilities with international wings. Leading centres in Guangzhou and Beijing provide English-speaking coordination. They use precise therapies like NanoKnife and cryosurgery to treat complex, solid tumours.
Bookimed Expert Insight: Oncology patients often find that high-volume centres in Guangzhou specialise in organ-sparing techniques. Dr Niu Lizhi has performed nearly 10,000 cryosurgeries. This volume is rarely seen in single Australian centres. This vast clinical experience often allows doctors to treat cases considered inoperable elsewhere.
Patient consensus: Patients from Commonwealth countries highlight the modern equipment. They note that Chinese specialists often focus on saving organs rather than removal. The wards are often described as similar to five-star rooms with helpful staff. Dedicated translation support also helps to ease the journey.
Traditional Chinese Medicine (TCM) is fully integrated into oncology care in China through a dual-system framework. Hospitals such as Jinshazhou Hospital of Guangzhou University of Chinese Medicine use TCM as supportive therapy. It is used alongside chemotherapy and immunotherapy to manage side effects and bolster immune function.
Bookimed Expert Insight: Clinical data shows that the most effective integration occurs in university-affiliated hospitals. For example, Jinshazhou Hospital uses its link with Guangzhou University of Chinese Medicine to standardise herbal treatments. This helps prevent TCM from interfering with modern therapies like Keytruda or NanoKnife. Such treatments are common in these high-volume centres.
Patient Consensus: Patients in China describe TCM as a helpful way to manage side effects and improve energy. Many value having local translators and 5-star room facilities. These amenities support those receiving both modern immunotherapy and traditional herbal support.